ADMA Ultrasensitive ELISA Assay Kit


The ADMA Ultrasensitive ELISA is an Enzyme-linked immunosorbent assay used for the quantitative and very sensitive determination of ADMA (Asymmetric Dimethylarginine) in human / mouse / rat plasma and serum samples as well as cell culture samples.  The ADMA Ultrasensitive ELISA Assay kit is for research use only and should not be used in diagnostic procedures.

ADMA Ultrasensitive ELISA Assay Kit

ADMA Ultrasensitive ELISA Assay Kit Developed and Manufactured in Germany by DLD Diagnostika EA209/96K/em>

Size: 1×96 wells
Sensitivity: 0.01 µmol/l
Dynamic Range: 0.01 – 5 µmol/l
Incubation Time: Overnight
Sample Type: Serum, Plasma, Cell Culture
Species Sample: Human, Mouse, Rat
Sample Size: 20 µL
Alternative Names: Asymmetric Dimethylarginine
For Research Use Only

Controls Included

Assay Principle

The new ADMA Ultrasensitive ELISA Assay Kit is a competitive and high sensitive ELISA that uses the microtiter plate format. ADMA is bound to the solid phase of the microtiter plate. ADMA in the samples is acylated and competes with solid phase bound Asymmetric Dimethylarginine for a fixed number of rabbit anti-ADMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-antiserum complexes are removed by washing. The antibody bound to the solid phase ADMA is detected by anti-rabbit/peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase ADMA is inversely proportional to the ADMA concentration of the sample.

Products Related to ADMA Ultrasensitive ELISA

ADMA Arginine ELISA Assay Kit
Mouse / Rat ADMA ELISA

For a Full Listing of Publications utilizing these ADMA ELISA’s, click on the link below:

ADMA ELISA Assay Kit Publications

Learn more about ADMA at Eagle Biosciences Biomarker Spotlight page dedicated to ADMA here:
ADMA Biomarker Spotlight

Additional Information

Assay Background

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an “endogenous anti-atherogenic molecule” due to its diverse regulatory functions in vascular homeostasis. NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be down-regulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS.

The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including patients with hypercholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular events and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

Assay Procedure

  1. Prepare all reagents, standard curve and samples as directed in the previous section.
  2. Pipette 50 µl of samples, standards or diluent (as negative control) into the wells.
  3. Immediately add 50 µl of HRP conjugate to each well.
  4. Mix gently.
  5. Seal wells with adhesive strip and incubate for 2 hours at room temperature.
  6. Aspirate fluid from wells and wash three times with 300 µl wash buffer. After the last wash, invert the plate and tap on a clean paper towel.
  7. Dispense 100 ml of TMB substrate solution into each well.
  8. Incubate for 20 minutes at room temperature in the dark.
  9. Add 100 µl of stop solution to each well.
  10. Determine the absorbance within 30 minutes at 450 nm. A reference wavelength of 620 nm/690 nm is recommended.

Typical Standard Curve

ADMA Ultrasensitive ELISA Assay


Product Manual